In keeping with the dual role of IFN signaling in both inhibiting and promoting anti-tumor immunity, treatment of YUMM3.3 melanoma-bearing mice with JAK1/2 inhibitors drastically accelerated the growth of Ctrl tumors, thereby minimizing the difference compared to the growth rate of βA tumors. Here, JAK1 is linked to melanoma.